Ye et al [19] performed a randomized, open-label, phase II, multicenter clinical trial in patients with advanced HNSCC and recurrent or metastatic NPC using paclitaxel and cisplatin with or without adenovirus-encapsulated endostatin (E10A) administered by intratumoral injection. This evidence concerns the gene COL18A1 and head and neck squamous cell carcinoma.